Edwards Lifesciences Corp (NYSE:EW) Holdings Cut by Meiji Yasuda Life Insurance Co

Meiji Yasuda Life Insurance Co reduced its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 10.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 6,511 shares of the medical research company’s stock after selling 795 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Edwards Lifesciences were worth $1,246,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in EW. Oregon Public Employees Retirement Fund raised its stake in Edwards Lifesciences by 21,360.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 10,587,326 shares during the period. Norges Bank acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $559,646,000. Jennison Associates LLC raised its stake in Edwards Lifesciences by 184.7% during the 4th quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock valued at $629,855,000 after purchasing an additional 2,667,749 shares during the period. FMR LLC raised its stake in Edwards Lifesciences by 28.9% during the 4th quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock valued at $1,160,540,000 after purchasing an additional 1,700,199 shares during the period. Finally, BlackRock Inc. raised its stake in Edwards Lifesciences by 7.4% during the 4th quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock valued at $2,516,802,000 after purchasing an additional 1,128,082 shares during the period. 82.12% of the stock is currently owned by institutional investors.

Shares of NYSE EW traded down $1.18 during mid-day trading on Wednesday, reaching $184.42. The company had a trading volume of 29,135 shares, compared to its average volume of 1,272,425. Edwards Lifesciences Corp has a twelve month low of $134.53 and a twelve month high of $197.86. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $38.07 billion, a PE ratio of 39.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.85.



Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business had revenue of $993.00 million for the quarter, compared to the consensus estimate of $989.87 million. During the same period in the prior year, the business posted $1.22 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.0% compared to the same quarter last year. As a group, analysts predict that Edwards Lifesciences Corp will post 5.29 EPS for the current year.

EW has been the topic of several recent analyst reports. Citigroup boosted their target price on shares of Edwards Lifesciences from $119.00 to $130.00 and gave the company a “sell” rating in a research note on Monday, February 25th. UBS Group boosted their target price on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Tuesday, March 12th. Canaccord Genuity reissued a “buy” rating and set a $215.00 target price (up from $190.00) on shares of Edwards Lifesciences in a research note on Monday, March 18th. Bank of America boosted their target price on shares of Edwards Lifesciences from $190.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, Wells Fargo & Co boosted their target price on shares of Edwards Lifesciences from $188.00 to $202.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $186.52.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 3,000 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $169.60, for a total transaction of $508,800.00. Following the transaction, the vice president now directly owns 20,674 shares of the company’s stock, valued at $3,506,310.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Larry L. Wood sold 6,716 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $192.34, for a total transaction of $1,291,755.44. Following the transaction, the vice president now directly owns 122,495 shares in the company, valued at $23,560,688.30. The disclosure for this sale can be found here. Insiders have sold 121,656 shares of company stock worth $21,713,940 over the last three months. Company insiders own 1.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://dakotafinancialnews.com/2019/06/12/edwards-lifesciences-corp-nyseew-holdings-cut-by-meiji-yasuda-life-insurance-co.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: What kind of dividend yield to CEF’s pay?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.